<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04560010</url>
  </required_header>
  <id_info>
    <org_study_id>20-00803</org_study_id>
    <nct_id>NCT04560010</nct_id>
  </id_info>
  <brief_title>TXA in Anticoagulated Patients Study</brief_title>
  <official_title>The Effect of Tranexamic Acid in Anticoagulated Patients Undergoing Total Shoulder Athroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, single-blind, single-center study comparing calculated total blood&#xD;
      loss, surgical drain output and hematoma formation in anticoagulated patients who receive 2&#xD;
      doses of Tranexamic Acid (TXA) versus control group undergoing anatomical and reverse total&#xD;
      shoulder arthroplasty. Patients will be randomized to either receive 2 doses of IV TXA, first&#xD;
      dose prior to surgical incision and second dose given 3 hours later or to the control group,&#xD;
      where no TXA will be administered.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2020</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">September 21, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects scheduled to undergo TSA (anatomic and reverse) will be randomized to receive one of two treatment options. This study will utilize a simple randomization approach to generate two-equal groups. All subjects have an equal chance (1:2) of getting randomized into one of the twp treatments groups: (1) Two doses of IV TXA, one before incision and the second 3 hours later. (2) control group - no TXA given. Randomization of each subject will be done on day of surgery. The randomization schedule will be generated using a computer software program such as randomization.com</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Neither the anesthesiologist or surgeon will be blinded to the patient's group assignment, as they will be the one performing the treatment. All other stakeholders (patient, other caregivers, and research staff collecting the data) will be blinded to the patient's group assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pre-operative to POD 1 hemoglobin levels</measure>
    <time_frame>Baseline to 24 hours post op</time_frame>
    <description>On Post Operative Day 1, the floor nurse will draw and send a post op hemoglobin/hematocrit panel for all study patients prior to discharge.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Surgical drain output</measure>
    <time_frame>0-24 hours post op</time_frame>
    <description>Surgical drain output will be recorded by floor nurse every 8 hours in EPIC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Formation of Hematoma</measure>
    <time_frame>2 weeks</time_frame>
    <description>(yes or no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Post op blood transfusion</measure>
    <time_frame>0-24 hours post op</time_frame>
    <description>(yes or no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative time</measure>
    <time_frame>~1-4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of adverse events</measure>
    <time_frame>until 30 days after last day of study participation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Total Shoulder Athroplasty</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TXA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no TXA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid Injection</intervention_name>
    <description>Injection of 1 gram of IV TXA before surgical plus 1 gram of IV TXA three hours later</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Patients older than 18 years old&#xD;
&#xD;
          -  Patients undergoing scheduled primary anatomic total shoulder arthroplasty&#xD;
&#xD;
          -  Patients undergoing scheduled primary reverse total shoulder arthroplasty&#xD;
&#xD;
          -  Patients who consent to be randomized&#xD;
&#xD;
          -  Preoperative use of anticoagulant or antiplatelet therapy within 10 days prior to&#xD;
             surgery:&#xD;
&#xD;
               -  Coumadin (Warfarin)&#xD;
&#xD;
               -  Heparin&#xD;
&#xD;
               -  Low molecular weight heparin&#xD;
&#xD;
               -  Factor Xa inhibitors&#xD;
&#xD;
               -  Apixaban (Eliquis)&#xD;
&#xD;
               -  Rivarixaban (Xatelto)&#xD;
&#xD;
               -  Edoxaban (Savaysa)&#xD;
&#xD;
               -  Dabigatran (Pradaxa)&#xD;
&#xD;
               -  Clopidogrel (Plavix)&#xD;
&#xD;
               -  Prasugrel (Effient)&#xD;
&#xD;
               -  Ticagrelor (Brilinta)&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Patients younger than 18&#xD;
&#xD;
          -  Patients who are pregnant* or breast-feeding women&#xD;
&#xD;
          -  Patients who are allergic to tranexamic acid&#xD;
&#xD;
          -  Patients scheduled for revision total shoulder arthroplasty&#xD;
&#xD;
          -  Patients with proximal humerus fracture or fracture sequelae&#xD;
&#xD;
          -  Patients who use estrogen containing medications (i.e. oral contraceptive pills)&#xD;
&#xD;
          -  Patients who have acquired disturbances of color vision&#xD;
&#xD;
          -  Patients with a history of any of the following diagnosis: '&#xD;
&#xD;
               -  Subarachnoid hemorrhage&#xD;
&#xD;
               -  Active intravascular clotting&#xD;
&#xD;
               -  Severe pulmonary disease (FEV &lt;50% normal)&#xD;
&#xD;
               -  Plasma creatinine &gt; 115 μmol/L in males, &gt; 100 μmol/L in females, or hepatic&#xD;
                  failure)&#xD;
&#xD;
               -  (Renal impairment serum creatinine &gt; 1.5 times the upper limit of normal NYU)&#xD;
&#xD;
               -  Preoperative anemia [Hemoglobin (Hb) &lt; 11g/dL in females, Hb &lt; 12 g/dL in males]&#xD;
&#xD;
          -  Patients who refuse blood products&#xD;
&#xD;
          -  Patients undergoing hormone replacement therapy&#xD;
&#xD;
          -  Patients with diagnosed or self-reported cognitive dysfunction;&#xD;
&#xD;
          -  Patients who are unable to understand or follow instructions;&#xD;
&#xD;
          -  Patients with severe liver disease, renal insufficiency, congestive heart failure,&#xD;
             and/or significant heart disease;&#xD;
&#xD;
          -  Patients with BMI over 50&#xD;
&#xD;
          -  Any patient that the investigators feel cannot comply with all study related&#xD;
             procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uchenna Umeh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Uchenna Umeh, MD</last_name>
    <phone>212-598-6085</phone>
    <email>Uchenna.Umeh@nyulangone.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juan Caruci</last_name>
    <email>Juan.Caruci@nyulangone.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uchenna Umeh, MD</last_name>
    </contact>
    <investigator>
      <last_name>Uchenna Umeh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 17, 2020</study_first_submitted>
  <study_first_submitted_qc>September 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2020</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to the PI. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>9 months and ending 36 months following article publication</ipd_time_frame>
    <ipd_access_criteria>Requests may be directed to the PI.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

